**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 69460

**Manuscript Type:** FRONTIER

**Peroral cholangioscopy: Update on the state-of-the-art**

Subhash A *et al*. Update on peroral cholangioscopy

Amith Subhash, James L Buxbaum, James H Tabibian

**Amith Subhash,** Department of Gastroenterology, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89102, United States

**James L Buxbaum,** Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of USC, Los Angeles, NV 90033, United States

**James H Tabibian,** David Geffen School of Medicine at UCLA, Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, United States

**James H Tabibian,** Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine at UCLA, Los Angeles, NV 90095, United States

**Author contributions:** Subhash A, Buxbaum JL, and Tabibian JH have all been involved in drafting the manuscript and/or making critical revisions; Subhash A, Buxbaum JL, and Tabibian JH meet the criteria for authorship established by the International Committee of Medical Journal Editors and approve the final manuscript for publication.

**Corresponding author: James H Tabibian, MD, PhD, Associate Professor,** David Geffen School of Medicine at UCLA, Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, 2B-182 Olive View Dr, Sylmar, CA 91342, United States. jtabibian@dhs.lacounty.gov

**Received:** June 30, 2021

**Revised:** August 25, 2021

**Accepted:** January 17, 2022

**Published online:** February 16, 2022

**Abstract**

Peroral cholangioscopy (POC) is an endoscopic procedure that allows direct intraductal visualization of the biliary tract. POC has emerged as a vital tool for indeterminate biliary stricture evaluation and treatment of difficult biliary stones. Over several generations of devices, POC has fulfilled additional clinical needs where other diagnostic or therapeutic modalities have been inadequate. With adverse event rates comparable to standard endoscopic retrograde cholangioscopy and unique technical attributes, the role of POC is likely to continue expand. In this frontiers article, we highlight the existing and growing clinical applications of POC as well as areas of ongoing research.

**Key Words:** Peroral cholangioscopy; SpyGlassTM; Difficult bile duct stones; Indeterminate biliary strictures; Cholangioscope-guided biopsy; Cholangioscope-guided lithotripsy

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Subhash A, Buxbaum JL, Tabibian JH. Peroral cholangioscopy: Update on the state-of-the-art. *World J Gastrointest Endosc* 2022; 14(2): 63-76

**URL:** https://www.wjgnet.com/1948-5190/full/v14/i2/63.htm

**DOI:** https://dx.doi.org/10.4253/wjge.v14.i2.63

**Core Tip:** Cholangioscopy is an endoscopic technique that was first developed in the 1970s as a minimally-invasive modality for the evaluation of various biliopancreatic pathologies. Since the advent of the digital single-operator cholangioscopy (D-SOC) in 2015 as well as other, complementary advancements in the field, diagnostic and therapeutic applications have further expanded. Herein, we discuss the various current applications of cholangioscopy, with a focus on D-SOC, and areas of ongoing research to better understand potential future directions.

**INTRODUCTION**

Endoscopic retrograde cholangiopancreatography (ERCP) was first reported in 1968 as a method to cannulate the major duodenal papilla[1]. It is now widely utilized as the primary interventional modality for many biliopancreatic disorders. Despite its vast utility, ERCP technique relies on indirect visualization of the biliary tree *via* fluoroscopy; this can be limiting for certain diagnostic and/or therapeutic applications (*e.g.* evaluation of biliary strictures, mapping of intraductal tumors for operative planning, tumor-directed ablative therapy, *etc.*).

In order to provide direct visualization of the biliopancreatic tree, peroral cholangioscopy (POC) was introduced in the 1970s[2,3]. POC was originally designed as a “mother-baby” system that required two endoscopists to operate the “mother” duodenoscope and “baby” cholangioscope[2]. In addition to the multi-operator requirement, there was a notable deficiency in this setup in the ability to acquire tissue following visualization, thus further limiting its use. Moreover, the initial scopes provided only two-way tip deflection, were fragile, and costly[4].

Over the past several decades, technologic improvements in the equipment utilized for POC has led to more widespread adoption and a growing number of applications (Figure 1). In the early 2000s, a new single-operator duodenoscope-assisted cholangioscopy technique utilizing a Pentax cholangioscope (FCP-8P/FCP-9P, Pentax Precision Instruments, Orangeburg, New York, United States) was introduced. However, this technique required the use of an endoscopist-worn breastplate to mount the cholangioscope, which allowed for manipulation of the duodenoscope with the left hand and the cholangioscope with the right hand[5]. In 2005, Boston Scientific released the first commercially available single-operator cholangioscopy (SOC) system (SpyGlassTM, Boston Scientific Corporation, Natick, MA, United States), a catheter-based system that utilizes an optical probe inserted through the duodenoscope working channel[6]. Ten years later, a digital SOC (D-SOC) system was introduced (SpyGlassTM DS, Boston Scientific Corporation)[6]; this updated digital system brought improvements in image size and quality, a wider field of view, and a redesigned working channel allowing for larger diameter cholangioscopic accessories, among other changes[4,7]. In 2018, a third generation SpyScopeTM DSII Catheter (Boston Scientific Corporation) featuring increased resolution and improved lighting was introduced alongside new cholangioscopic accessories. Alternatively, direct POC (DPOC) can be performed utilizing a modern ultraslim upper endoscope that can be advanced into the biliary tree following endoscopic sphincterotomy, a technique first published in a pilot study in 2006[8–10]; however, this setup is primarily used outside the United States and available in only select markets[7].

Given the recent technologic advancements in POC, its array of accessories (Figure 2), and improved training of advanced endoscopists, there has been wide propagation of this technique across most large medical centers. In this Frontiers article, we aim to underscore the major developments in the growing body of literature on POC, with particular emphasis on SOC and D-SOC, including diagnostic and therapeutic applications as well as established and investigational indications.

**COMMON APPLICATIONS OF CHOLANGIOSCOPY**

***Management of difficult biliary stones***

Approximately 10%-18% of patients with symptomatic cholelithiasis will have concomitant choledocholithiasis[11]. The standard of care for these patients is ERCP with endoscopic sphincterotomy followed by stone extraction with a balloon or basket[4,11]. In a minority of cases, bile duct stones may be more difficult to extract, requiring additional measures[12]. Difficult bile duct stones have been previously defined as large size (> 1.5 cm in diameter), impacted stones in the bile or cystic duct, intrahepatic location, hard stone consistency, stricture distal to stones, and/or anatomical variants (*e.g.* unusual size/shape of bile duct) posing technical challenges[12,13].

POC allows for direct visualization and decreased risk of bile duct injury and is a vital addition to the ERCP armamentarium for stone disease. Indeed, a recent meta-analysis found the estimated success rate for difficult bile duct stone clearance to be 88% [95% confidence interval (CI): 85%-91%] across 820 patients (*n* = 31 studies)[14]. Furthermore, POC was found to have a low adverse event (AE) rate of 7% (95%CI: 6%-95%), comparable to ERCP[14,15]. Thus, POC is a valuable modality in addition to or in lieu of conventional ERCP methods such as mechanical lithotripsy (ML) and endoscopic papillary large balloon dilation (EPLBD).

Since the time of publication of the aforementioned meta-analysis, three randomized controlled trials (RCTs) comparing POC-guided electrohydraulic lithotripsy (EHL) or holmium laser lithotripsy (LL) *vs* conventional therapy (*i.e.* ML, EPLBD, and balloon extraction) have been published. In the first study, the investigators randomized patients with bile duct stones > 1 cm in diameter in a 2:1 ratio to SOC-guided LL *vs* conventional therapy. Stone clearance was achieved in 39 of 42 (93%) patients treated with SOC-guided LL compared to 12 of 18 (67%) treated with conventional therapy (*P* = 0.009). AE rates were similar in the two treatment groups[16]. In the second study, successful stone removal did not differ in the SOC-guided EHL arm (37 of 48) *vs* conventional therapy arm (36 of 50) (*P* > 0.05); similarly, crossover yielded non-statistically significant differences in the two groups (successful stone removal in 40 of 47 patients *vs* 42 of 44 patients, *P* > 0.05)[17]. In the final study, the investigators randomized 32 patients with large CBD stones in whom sphincterotomy and/or EPLBD had failed into ML or D-SOC-guided LL treatment arms. Crossover was permitted as a rescue treatment if the primarily assigned technique failed to achieve stone clearance. Stone clearance rates for ML and D-SOC-guided LL groups were 63% and 100%, respectively (*P* < 0.01). In six patients, ML was considered a failure; when crossed over to LL, four of these patients achieved stone clearance in the same session, and the remaining two patients achieved stone clearance in subsequent LL sessions. AEs were reported at similar rates, 13% in the ML group and 6% in the LL group (*P* = 0.76). The median length of hospital stay following the respective procedures was 1 d in both groups (*P* = 0.27). At six months follow-up, neither group had recurrent cholangitis or evidence of recurrent CBD stones[18]. While the RCT data presented above may appear mixed or only partially in favor of POC in the management of difficult bile duct stones, it is important to note that only the last of the three studies discussed above utilized the newer generation of D-SOC. Thus, additional RCT data using the contemporary D-SOC system is needed.

POC can also be utilized to confirm stone clearance in cases of choledocholithiasis. In a retrospective study of 36 patients who underwent ERCP with EPLBD for difficult biliary stones, DPOC was performed immediately after a negative balloon-occluded cholangiography[19]. In 31 of 36 patients (86%), technical success was achieved with hepatic hilum visualization. Residual stones were found in 7 of these 31 patients (22.5%) upon DPOC, among which 4 patients underwent successful stone extraction during the same DPOC session. The remaining 3 patients underwent secondary ERCP for residual stone removal. There were no reported AEs in the study.

***Indeterminate biliary strictures***

**Visual evaluation:** Another major indication for POC is the evaluation of indeterminate biliary strictures (IDBSs). IDBSs are defined as biliary strictures of persistent unclear etiology following cross-sectional imaging and evaluation by ERCP with brush cytology or intraductal biopsies[20]. In a meta-analysis of 16 studies including 1556 patients, the overall sensitivity of conventional cytology from ERCP was found to be 41.6% (99%CI: 38.4%-44.8%), with a negative predictive value of 58.0% (99%CI: 54.8%-61.2%)[21]. This study and others, as well as widespread clinical experience, attest to the need for improved diagnostic capability for IDBSs.

The visual diagnosis of intraductal lesions can be aided by direct visualization during POC (Figure 3). Currently, there is no widely accepted classification system for visual diagnosis; however, some cholangioscopic findings are highly suggestive of malignancy in the appropriate clinical context. These findings include the presence of neovascularization, mucosal changes and projections, and intraductal nodules, among others[22–24]. Historically, neovascularization, also termed “tumor vessels,” has had the most consensus regarding its description and malignant implications[24]. It has been described as irregularly dilated, tortuous, and abnormally proliferating vessels on the mucosa adjacent to a stricture.

In a recent systematic review and meta-analysis of 21 studies examining the diagnostic performance characteristics of POC-based visual assessments of IDBSs, the pooled sensitivity and specificity for establishing a malignancy diagnosis were 88% (95%CI: 83%-91%) and 95% (95%CI: 89-98%), respectively[25]. Subgroup analysis of studies that utilized D-SOC found a higher sensitivity for visual diagnosis [94% (95%CI: 89%-97%)] compared to D-SOC-guided biopsy [79% (95%CI: 72%-84%), *P* < 0.001] while also showing a higher specificity for D-SOC-guided biopsy [100% (95%CI: 97%-100%)] compared to D-SOC visual impression [86% (95%CI: 76%-92%), *P* < 0.001][25]. Subgroup analysis of studies that utilized DPOC did not reveal statistically significant differences in performance characteristics of visual impression *vs* DPOC-guided biopsy (possibly suggesting superior optical performance of DPOC compared to D-SOC), though power was limited[25]. Overall, performance characteristics of visual impression utilizing modern POC (both D-SOC and DPOC) appears promising.

A recent group of researchers have produced a new schema, the “Monaco Classification,” in order to attempt to standardize visual criteria in evaluating IDBSs as malignant *vs* benign. Twelve expert biliary endoscopists from around the world reviewed 40 video clips (13 benign pathology, 27 malignant) in order to consolidate visual criteria into the following: (1) Presence of stricture (symmetric or asymmetric); (2) Presence of lesion (with associated mass, nodule, or polypoid in appearance); (3) Smooth or granular mucosal features; (4) Papillary projections; (5) Ulceration; (6) Abnormal vessels; (7) Scarring (local or diffuse); and (8) Pronounced pit pattern[26]. Thereafter, 21 D-SOC video clips were reviewed by 14 interventional endoscopists utilizing these criteria, ranging from slight to moderate in interobserver agreement[26]. Diagnostic accuracy of visual interpretation of malignant *vs* benign pathology was 70% based on the new criteria, compared to an average accuracy less than 50% on prior attempts to establish visual criteria[26,27]. While the Monaco Classification has taken a crucial step in a forward direction, it would benefit from further refinement and validation.

**Cytopathologic evaluation:** In addition to the visual diagnosis of IDBSs, POC-guided biopsy can provide further histopathologic interpretation of IDBSs. In a systematic review with meta-analysis of 10 studies evaluating the use of SOC-guided biopsy for the diagnosis of malignant biliary strictures, the overall pooled sensitivity and specificity were 60.1% (95%CI: 54.9%-65.2%) and 98.0% (95%CI: 96.0%-99.0%), respectively[28]. In a subset of four studies, patients (*n* = 148) had previously undergone ERCP with benign or non-diagnostic brushing/biopsy results (with strong suspicion for malignancy); in this specific cohort, the pooled sensitivity and specificity of SOC-guided biopsy were 74.7% (95%CI: 63.3%-84.0%) and 93.3% (95%CI: 85.1%-97.8%), respectively[28]. More recently, a systematic review with meta-analysis of 11 studies examined the use of D-SOC-guided biopsy for evaluation of IDBSs. The pooled sensitivity and specificity were 74% (95%CI: 67%-80%) and 98% (95%CI: 95%-100%), respectively[29]. These data suggest that POC-guided biopsy, in particular D-SOC-guided biopsy, yields improved diagnostic sensitivity when evaluating IDBSs.

POC-guided biopsies can be useful in cases where prior ERCP biopsies/brushings return benign or non-diagnostic results (when a strong suspicion for malignancy nevertheless remains) (Figure 3). In addition, a retrospective study of 40 patients found that biliary lavage cytology can be combined with POC-guided biopsy to further improve diagnostic sensitivity and accuracy when compared to POC-guided biopsy alone (sensitivity 88% *vs* 70% and accuracy 90% *vs* 75%, respectively)[30]. Of note, the data presented above predates the advent of the SpyBiteTM Max biopsy forceps, which has increased tissue capacity compared to the first-generation SpyBite (legacy) forceps. This, along with other improvements, is expected to further improve the diagnostic performance of POC-guided intraductal biopsy.

One limiting factor that has been thought to potentially hamper the utility of SOC-guided biopsy is the absence of on-site cytopathology for real-time tissue processing, a concern recently addressed by the SOCRATES (single-operator cholangioscopy randomized trial evaluating specimens) trial[31]. In this RCT, patients (*n* = 62) with IDBSs were randomized to an off-site tissue processing cohort (*n* = 30) and an on-site cohort (*n* = 32) in order to compare diagnostic accuracy. The study found a diagnostic accuracy of 90% (95%CI: 73.5%-97.9%) versus 84.4% (95%CI: 67.2%-94.7%) when comparing off-site tissue processing *vs* on-site, respectively (*P* = 0.86). Additionally, the overall treatment costs of D-SOC based on the Medicare reimbursement fee structure (including anesthesia, hospital fees, laboratory fees, medications, supplies, and radiologic fees) was found to be $14423 for the off-site cohort compared to $13015 for the on-site cohort (*P* = 0.60). Thus, this RCT suggests that D-SOC is a cost-effective option for the evaluation of IDBSs, even in centers without on-site cytopathology.

***Primary sclerosing cholangitis***

Primary sclerosing cholangitis (PSC) is a chronic, progressive disease that causes inflammation and fibrosis of the biliary tract, often leading to end-stage liver disease and/or cholangiocarcinoma (CCA)[32]. Patients with PSC can develop “dominant strictures,” or focal narrowing defined at ERCP as stenosis with diameter ≤ 1.5 mm in the CBD and/or ≤ 1.0 mm in a hepatic duct within 2 cm of the ductal confluence[20,32–34]. Dominant strictures are clinically significant in light of their higher propensity for bacterial cholangitis and for underlying dysplasia or carcinoma[32,35]. A recent systematic review and meta-analysis of 21 studies found the that the pooled sensitivity and specificity of POC for diagnosis of CCA was 65% (95%CI: 35%-87%) and 97% (95%CI: 87%-99%), respectively[36]. POC-guided biopsy also had the highest diagnostic accuracy (96%), compared to bile duct brushings (87%), fluorescence *in situ* hybridization (FISH) (69% for polysomy and 47% for trisomy), and probe-based confocal laser endomicroscopy (75%)[36].

However, not all data to date support the use of POC in patients with PSC. For example, a prospective study of 47 patients with PSC evaluating the use of POC-guided biopsy of strictures found a significantly lower sensitivity (33%) than previously reported[37]. Additionally, a retrospective study of 92 patients, both with (*n* = 36) and without (*n* = 56) PSC, examined the performance characteristics of ERCP with brush cytology, FISH, POC-guided biopsy, transpapillary biopsy and each possible combination of the aforementioned for the detection of CCA. When combining all diagnostic modalities, patients without PSC showed a trend towards improved sensitivity compared to brush cytology alone (75% *vs* 40.9%, *P* = 0.06)[38]. However, the PSC group did not show a similar trend towards improved sensitivity when comparing all four diagnostic modalities to cytology alone (60% *vs* 50%, *P* = 1)[38].

Overall, the precise role of POC in the diagnostic evaluation of dominant strictures in PSC remains unclear. POC can potentially play an important role in studying the natural history and progression of PSC and in general facilitate better characterization and sampling of dominant strictures. For instance, with the newly proposed cholangioscopy-based “Edmonton Classification” system for phenotypic classification, dominant strictures can be classified into one of the three following phenotypes: Inflammatory, fibro-stenotic, or nodular or mass-forming. One theory is that these and other POC findings may differ by disease stage/pathobiological involvement (*e.g.* nodular or mass forming may be indicative of developing or nascent CCA)[39]. It is proposed that combining phenotypic data with histopathology, biochemical markers, and cholangiography scores over time could lead to improved management algorithms[40]. For now, validation of this classification system remains the initial step prior to determining its ultimate clinical utility.

***Evaluation of intraductal neoplasms***

POC is becoming increasingly useful in the mapping of biliopancreatic neoplasms such as CCA and intraductal papillary mucinous neoplasms (IPMNs). With improved visual delineation of neoplastic margins in the biliary tree and pancreatic ducts, staging can be more precise, and thus a better-informed therapeutic plan can be formulated (Figure 3). A multicenter prospective cohort study of 118 patients evaluated the impact of cholangiopancreatoscopy on preoperative assessment of biliopancreatic neoplasms. Following cholangiopancreatoscopy, the initial therapeutic plan was altered in 34% of patients[41]. Of these patients, more extensive surgery was required in 10%, less extensive surgery was required in 65%, and surgery was avoided in the remaining 25%[41]. Additionally, the study reported a 88% correlation in histology between the surgical specimens and cholangiopancreatoscopy specimens[41].

Cholangiopancreatoscopy is also being utilized to directly examine pancreatic duct abnormalities, such as distinguishing between pancreatic duct dilation secondary to chronic pancreatitis *vs* IPMNs[42]. When used in conjunction with non-invasive imaging, POC/cholangiopancreatoscopy improves diagnostic and therapeutic ability. As has been discussed in prior sections, this is mainly from direct visual tissue inspection and the ability to obtain targeted biopsies. Simultaneously, it also offers the opportunity for facilitate therapeutic intervention (*e.g.* management of pancreatolithiasis).

***Selective guidewire placement***

Numerous case reports, series, and a retrospective study have all demonstrated the potential benefits of POC-guided guidewire placement across strictures of varying causes (malignant, post-OLT, PSC, *etc.*)[43–45]. In the retrospective study, a total of 23 patients with known biliary strictures in whom endoscopic guidewire placement had previously failed underwent 30 procedures; technical success (guidewire placement) was achieved in 70%[43]. Subgroup analysis demonstrated a higher technical success rate among benign biliary strictures *vs* malignant strictures (88% *vs* 46%, *P* = 0.02). Of the 23 patients, 7 underwent repeat procedures, both in patients with previous failure of guidewire placement (*n* = 3) and prior success of guidewire placement (*n* = 4). A higher technical success rate was demonstrated on initial exam compared to subsequent exams (78% *vs* 43%, *P* = 0.15)[43]. While data are limited, POC-guided guidewire placement can be an effective alternative option, though traditional ERCP approaches should be attempted primarily given the significantly higher costs associated with POC and the ability to potentially troubleshoot successfully with varying guidewire diameters, tip designs, tip core materials, *etc.* during ERCP.

***Biliary tumor ablation***

The use of POC-guided radiofrequency ablation (RFA) to provide locoregional cancer-directed therapy for the management of extrahepatic CCA or other intraductal malignancies has been presented in various case reports[46,47]. Historically, percutaneous RFA has been well studied, though this technique has demonstrated an association with various AEs[48]. ERCP-RFA (without POC) has thus been explored as a possible alternative in porcine models, yielding similar concerns for high AE rates[49]. In a review article, the pooled data from 12 studies evaluating endoscopic RFA treatment for the management of patients with unresectable malignant biliary strictures showed similarly high AE rates (16%) across 318 total patients[50]. In a retrospective study of 12 patients, POC-guided RFA was both technically (RFA probe insertion into stricture site) and clinically successful (tumor ablation with POC imaging) while demonstrating safety (1 AE in study population) and efficacy in maintaining stent patency (median of 154 d) following POC-guided RFA. Though data are limited, POC-guided RFA could be explored in further studies as a potentially viable, safer (compared to percutaneous RFA and endoscopic RFA) palliative treatment option for select patients with unresectable malignant biliary strictures.

POC-guided photodynamic therapy (PDT) has also been suggested to improve symptoms and prolong survival in cases of unresectable biliary tumors, with relatively few complications[51]. PDT begins with the administration of intravenous photosensitizer, which is preferentially retained by malignant tissue, approximately 24 h prior to POC. Subsequently, light energy can be delivered under POC guidance to the target tissue at a photoactivating wavelength, resulting in a photochemical reaction inducing ischemia and necrosis of tumor cells[52]. RCT data is limited to ERCP-based studies, in which PDT plus endoscopic stenting (*n* = 20) *vs* endoscopic stenting alone (*n* = 19) found improvement in median survival (493 d *vs* 98 d, *P* < 0.0001)[53]. However, a retrospective case series (*n* = 45) demonstrated similar absolute increases in median survival time when comparing SOC-guided PDT *vs* PDT-only, though not statistically significant (386 d *vs* 200 d, *P* = 0.45)[51]. This may suggest that larger cohorts need to be studied to better understand whether the effect of SOC-guided PDT truly plays an essential role compared to PDT therapy alone.

***Post-liver transplant biliary complications***

One AE orthotopic liver transplantation (OLT) patients face is the development of biliary strictures, either anastomotic (more common) or nonanstomotic (less common). Biliary strictures affect up to nearly 40% of post-OLT patients[54]. In these cases, POC can be utilized for visual assessment of the biliary epithelium and/or targeted biopsy, if needed[55]. Additionally, some strictures are not amenable to guidewire insertion or cannulation with standard ERCP (*e.g.* angulated strictures)[56]; the addition of POC can facilitate guidewire insertion and possibly obviate the need for biliary drainage or surgical intervention[55,56].

In a recent observational study of 26 patients who underwent ERCP followed by POC for suspected biliary complications post-OLT, 33 biliary complications were found in 22 patients. The remaining 4 patients were found to have normal bile ducts. Of the biliary complications, anastomotic strictures were the most common (14), followed by nonastomotic strictures (7), biliary stones (6), and lastly biliary casts (3). In 12 patients (46%), POC demonstrated a clear benefit: Selective guidewire placement, identification of biliary cast and/or stones not previously found on ERCP, or epithelial changes (*e.g.* ulceration or inflammation) secondary to infection[44]. Additional case series have shown the potential benefits of POC-guided steroid injections for management of anastomotic strictures and POC-guided guidewire placement across strictures (previously failed under fluoroscopic guidance)[56,57]. All of these observational studies suggest low rates of AEs, even in the post-OLT population[44,56,57]. Of note, in immunocompromised post-OLT patients, it is important to provide a prophylactic course of antibiotics given the potential increased risk of bacterial translocation with POC[58].

***Radiation-free management***

One of the disadvantages of conventional ERCP therapy is radiation exposure to patients and medical staff from the use of fluoroscopy. In particular, there can be teratogenic risk posed to pregnant patients in the first trimester[59]. While ERCP remains the standard of care and every effort should be made to use fluoroscopy selectively and with proper safety measures, POC can be utilized as an alternative management strategy to minimize or obviate the use of radiation[60]. A recent retrospective, multicenter study demonstrated 100% success rate in achieving bile duct cannulation without the use of fluoroscopy in the study population of pregnant patients (*n* = 10) with a mean gestational age of 23 wk. Indications for intervention included: Choledocholithiasis (7), stent removal (1), biliary stricture (1), and combined choledocholithiasis/stent removal (1). Fifty-percent of patients were able to undergo a completely radiation-free procedure, while an additional 30% received a dose minimized below the recommended amount. AEs (pancreatitis[1], mild bleeding[1]) occurred in two patients (20%)[61]. The data remain limited in this cohort, but this application of POC can certainly be considered as a possibly safer alternative in select cases[61–63].

**EMERGING AND MISCELLANEOUS APPLICATIONS OF CHOLANGIOSCOPY**

Novel applications of POC continue to emerge. One area of demonstrated utility has been in the removal of migrated stents and other foreign bodies. Following failed retrieval attempts with ERCP, POC can provide better visualization and/or access for successful extraction, thereby avoiding more invasive procedures[64–67]. Additionally, POC can aid in the evaluation and management of hemobilia. After magnetic resonance cholangiopancreatography (MRCP) or ERCP demonstrates the presence of blood in the bile duct, POC can facilitate determining the source and etiology of bleeding. In one case report, POC was utilized to confirm hemobilia arising from the gallbladder, and ultimately a diagnosis of diffusely infiltrative gallbladder cancer was made[68]. Another case report describes the detection of biliary angiodysplasia during POC following an unrevealing MRCP[69]. There have also been reports of the use of POC in select cases of cholecystitis, where patients may not otherwise be surgical candidates and/or in the presence of anatomical challenges. In these instances, POC can be utilized to access and traverse the cystic duct with subsequent deployment of metal or plastic stents as a means of minimally-invasive management[70-72]. Finally, there has been a reported case of POC-guided EHL for the removal of a calcified stool bezoar in an elderly patient with chronic, severe constipation[73].

**DRAWBACKS OF CHOLANGIOSCOPY: ECONOMIC CONSIDERATIONS AND AEs**

Though the clinical applications of POC continue to expand, several factors hinder further widespread use. In particular, the financial implications of POC *vs* conventional ERCP, owing to the high cumulative costs of the POC processor, cholangioscopes, and cholangioscopic accessories, are major hindering factors. Overall, start-up costs have been estimated to range between 50000 to $90000, though they can vary substantially by institutional contract[74]. Additionally, cholangioscopes (D-SOC) and their accessories are both single-use, and each one costs on the order of thousands and hundreds of dollars, respectively. Based on a micro-costing approach, one European study suggested that POC could be cost-effective for both treatment of difficult bile duct stones and diagnosis of IDBSs when compared to conventional ERCP[75]. However, robust economic data are lacking in the United States. Moreover, procedure times are often longer with POC when compared to conventional ERCP; thus, this may deter performance of POC due to the ability to generate more revenue with conventional ERCP *per* unit of time.

The overall AE rate associated with POC has been reported to be between 4% and 22%[76]. The major AEs include: Cholangitis, bacteremia, liver abscess, pancreatitis, and bleeding[77]. In a nationwide study in Sweden analyzing 36352 ERCP procedures and 408 cholangioscopy procedures between 2007 and 2012, reported post-procedural AEs were higher with POC when compared to ERCP (19.1% *vs* 14.0%)[78]. Pancreatitis (7.4% *vs* 3.9%) and cholangitis (4.4% *vs* 2.7%) showed similar increases, though multivariate analysis did not demonstrate a statistically significant difference when adjusted for confounders[78]. While higher rates of AEs with POC remain a concern, one group found that administration of peri-interventional antibiotics can substantially reduce rates of cholangitis[79]. With ongoing evolution of POC technology, its safety profile when directly compared to conventional ERCP will need continued assessment.

**RECENT AND FUTURE DEVICE DEVELOPMENT**

In May 2019, a next generation “mother-baby” videocholangioscope system (CHF-B290, Olympus Medical Systems Corporation, Tokyo, Japan) was introduced[80,81]. Despite being a newer iteration with notable improvements, some previously known limitations (*e.g.* two endoscopist operators and two equipment towers) remain, while others, such as scope fragility and accessory channel diameter, have been reported to be improved[80]. Currently, this system is only available for use in certain markets in Asia and Europe[80].

In July 2020, Ambu Inc. received FDA approval for the Ambu® aScopeTM (Ambu Inc, Columbia, MD United States) Duodeno, a single-use duodenoscope. It is anticipated that a single-use cholangioscope and additional accessories will follow in the next 1-2 years, with the potential for new clinical applications. It will be interesting to compare these developments to existing scopes and accessories.

**CONCLUSION**

With growing evidence to support its use, POC has evolved into an important tool in the biliopancreatic armamentarium. It is an important therapeutic option for difficult biliary stones and a core part of the evaluation of indeterminate strictures. Outcomes from the use of D-SOC for other ongoing and investigational indications (*e.g.* radiation-free intervention in pregnant patients, migrated stent/foreign body extraction, post-OLT biliary complication management, and selective guidewire placement) appear promising. Still, as discussed in this review, there are constraining factors and limitations to consider, *e.g.* device costs, paucity of standardized cholangioscopic visual classification systems, anatomical challenges, *etc.*[82].

In the future, further research and data are needed to solidify the evidence for POC and clarify the outcomes of its investigational applications. For now, endoscopists may continue to explore additional frontiers of clinical application, particularly with the advent of new accessories and further technologic enhancements that may be on the horizon.

**REFERENCES**

1 **McCune WS**, Shorb PE, Moscovitz H. Endoscopic cannulation of the ampulla of vater: a preliminary report. *Ann Surg* 1968; **167**: 752-756 [PMID: 5646296 DOI: 10.1016/S0016-5107(88)71332-2]

2 **Urakami Y**, Seifert E, Butke H. Peroral direct cholangioscopy (PDCS) using routine straight-view endoscope: first report. *Endoscopy* 1977; **9**: 27-30 [PMID: 862583 DOI: 10.1055/s-0028-1098481]

3 **Choi JH**, Lee SK. Percutaneous transhepatic cholangioscopy: does its role still exist? *Clin Endosc* 2013; **46**: 529-536 [PMID: 24143316 DOI: 10.5946/ce.2013.46.5.529]

4 **Ayoub F**, Yang D, Draganov PV. Cholangioscopy in the digital era. *Transl Gastroenterol Hepatol* 2018; **3**: 82 [PMID: 30505969 DOI: 10.21037/tgh.2018.10.08]

5 **Farrell JJ**, Bounds BC, Al-Shalabi S, Jacobson BC, Brugge WR, Schapiro RH, Kelsey PB. Single-operator duodenoscope-assisted cholangioscopy is an effective alternative in the management of choledocholithiasis not removed by conventional methods, including mechanical lithotripsy. *Endoscopy* 2005; **37**: 542-547 [PMID: 15933927 DOI: 10.1055/s-2005-861306]

6 **Hoffman A**, Rey JW, Kiesslich R. Single operator choledochoscopy and its role in daily endoscopy routine. *World J Gastrointest Endosc* 2013; **5**: 203-210 [PMID: 23678372 DOI: 10.4253/wjge.v5.i5.203]

7 **Ghersi S**, Fuccio L, Bassi M, Fabbri C, Cennamo V. Current status of peroral cholangioscopy in biliary tract diseases. *World J Gastrointest Endosc* 2015; **7**: 510-517 [PMID: 25992189 DOI: 10.4253/wjge.v7.i5.510]

8 **Larghi A**, Waxman I. Endoscopic direct cholangioscopy by using an ultra-slim upper endoscope: a feasibility study. *Gastrointest Endosc* 2006; **63**: 853-857 [PMID: 16650553 DOI: 10.1016/j.gie.2005.07.050]

9 **Parsi MA**. Direct peroral cholangioscopy. *World J Gastrointest Endosc* 2014; **6**: 1-5 [PMID: 24527174 DOI: 10.4253/wjge.v6.i1.1]

10 **Moon JH**, Choi HJ. The role of direct peroral cholangioscopy using an ultraslim endoscope for biliary lesions: indications, limitations, and complications. *Clin Endosc* 2013; **46**: 537-539 [PMID: 24143317 DOI: 10.5946/ce.2013.46.5.537]

11 **Dasari BV**, Tan CJ, Gurusamy KS, Martin DJ, Kirk G, McKie L, Diamond T, Taylor MA. Surgical *vs* endoscopic treatment of bile duct stones. *Cochrane Database Syst Rev* 2013: CD003327 [PMID: 23999986 DOI: 10.1002/14651858.CD003327.pub3]

12 **Carr-Locke DL**. Difficult bile-duct stones: cut, dilate, or both? *Gastrointest Endosc* 2008; **67**: 1053-1055 [PMID: 18513548 DOI: 10.1016/j.gie.2008.02.003]

13 **McHenry L**, Lehman G. Difficult bile duct stones. *Curr Treat Options Gastroenterol* 2006; **9**: 123-132 [PMID: 16539873 DOI: 10.1007/s11938-006-0031-6]

14 **Korrapati P**, Ciolino J, Wani S, Shah J, Watson R, Muthusamy VR, Klapman J, Komanduri S. The efficacy of peroral cholangioscopy for difficult bile duct stones and indeterminate strictures: a systematic review and meta-analysis. *Endosc Int Open* 2016; **4**: E263-E275 [PMID: 27004242 DOI: 10.1055/s-0042-100194]

15 **Andriulli A**, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. *Am J Gastroenterol* 2007; **102**: 1781-1788 [PMID: 17509029 DOI: 10.1111/j.1572-0241.2007.01279.x]

16 **Buxbaum J**, Sahakian A, Ko C, Jayaram P, Lane C, Yu CY, Kankotia R, Laine L. Randomized trial of cholangioscopy-guided laser lithotripsy versus conventional therapy for large bile duct stones (with videos). *Gastrointest Endosc* 2018; **87**: 1050-1060 [PMID: 28866457 DOI: 10.1016/j.gie.2017.08.021]

17 **Franzini T**, Moura RN, Bonifácio P, Luz GO, de Souza TF, Dos Santos MEL, Rodela GL, Ide E, Herman P, Montagnini AL, D'Albuquerque LAC, Sakai P, de Moura EGH. Complex biliary stones management: cholangioscopy *vs* papillary large balloon dilation - a randomized controlled trial. *Endosc Int Open* 2018; **6**: E131-E138 [PMID: 29399609 DOI: 10.1055/s-0043-122493]

18 **Angsuwatcharakon P**, Kulpatcharapong S, Ridtitid W, Boonmee C, Piyachaturawat P, Kongkam P, Pareesri W, Rerknimitr R. Digital cholangioscopy-guided laser *vs* mechanical lithotripsy for large bile duct stone removal after failed papillary large-balloon dilation: a randomized study. *Endoscopy* 2019; **51**: 1066-1073 [PMID: 30786315 DOI: 10.1055/a-0848-8373]

19 **Anderloni A**, Auriemma F, Fugazza A, Troncone E, Maia L, Maselli R, Carrara S, D'Amico F, Belletrutti PJ, Repici A. Direct peroral cholangioscopy in the management of difficult biliary stones: a new tool to confirm common bile duct clearance. Results of a preliminary study. *J Gastrointestin Liver Dis* 2019; **28**: 89-94 [PMID: 30851177 DOI: 10.15403/jgld.2014.1121.281.bil]

20 **Hilscher MB**, Tabibian JH, Carey EJ, Gostout CJ, Lindor KD. Dominant strictures in primary sclerosing cholangitis: A multicenter survey of clinical definitions and practices. *Hepatol Commun* 2018; **2**: 836-844 [PMID: 30027141 DOI: 10.1002/hep4.1194]

21 **Burnett AS**, Calvert TJ, Chokshi RJ. Sensitivity of endoscopic retrograde cholangiopancreatography standard cytology: 10-y review of the literature. *J Surg Res* 2013; **184**: 304-311 [PMID: 23866788 DOI: 10.1016/j.jss.2013.06.028]

22 **Seo DW**, Lee SK, Yoo KS, Kang GH, Kim MH, Suh DJ, Min YI. Cholangioscopic findings in bile duct tumors. *Gastrointest Endosc* 2000; **52**: 630-634 [PMID: 11060187 DOI: 10.1067/mge.2000.108667]

23 **Shah RJ**, Raijman I, Brauer B, Gumustop B, Pleskow DK. Performance of a fully disposable, digital, single-operator cholangiopancreatoscope. *Endoscopy* 2017; **49**: 651-658 [PMID: 28511237 DOI: 10.1055/s-0043-106295]

24 **Kim HJ**, Kim MH, Lee SK, Yoo KS, Seo DW, Min YI. Tumor vessel: a valuable cholangioscopic clue of malignant biliary stricture. *Gastrointest Endosc* 2000; **52**: 635-638 [PMID: 11060188 DOI: 10.1067/mge.2000.108969]

25 **Kulpatcharapong S**, Pittayanon R, Kerr SJ, Rerknimitr R. Diagnostic performance of digital and video cholangioscopes in patients with suspected malignant biliary strictures: a systematic review and meta-analysis. *Surg Endosc* 2021 [PMID: 34076761 DOI: 10.1007/s00464-021-08571-2]

26 **Sethi A**, Tyberg A, Slivka A, Adler DG, Desai AP, Sejpal DV, Pleskow DK, Bertani H, Gan SI, Shah R, Arnelo U, Tarnasky PR, Banerjee S, Itoi T, Moon JH, Kim DC, Gaidhane M, Raijman I, Peterson BT, Gress FG, Kahaleh M. Digital Single-operator Cholangioscopy (DSOC) Improves Interobserver Agreement (IOA) and Accuracy for Evaluation of Indeterminate Biliary Strictures: The Monaco Classification. *J Clin Gastroenterol* 2020 [PMID: 32040050 DOI: 10.1097/MCG.0000000000001321]

27 **Sethi A**, Doukides T, Sejpal DV, Pleskow DK, Slivka A, Adler DG, Shah RJ, Edmundowicz SA, Itoi T, Petersen BT, Gress FG, Gaidhane M, Kahaleh M. Interobserver agreement for single operator choledochoscopy imaging: can we do better? *Diagn Ther Endosc* 2014; **2014**: 730731 [PMID: 25400494 DOI: 10.1155/2014/730731]

28 **Navaneethan U**, Hasan MK, Lourdusamy V, Njei B, Varadarajulu S, Hawes RH. Single-operator cholangioscopy and targeted biopsies in the diagnosis of indeterminate biliary strictures: a systematic review. *Gastrointest Endosc* 2015; **82**: 608-14.e2 [PMID: 26071061 DOI: 10.1016/j.gie.2015.04.030]

29 **Wen LJ**, Chen JH, Xu HJ, Yu Q, Liu K. Efficacy and Safety of Digital Single-Operator Cholangioscopy in the Diagnosis of Indeterminate Biliary Strictures by Targeted Biopsies: A Systematic Review and Meta-Analysis. *Diagnostics (Basel)* 2020; **10** [PMID: 32887436 DOI: 10.3390/diagnostics10090666]

30 **Motomura Y,** Akahoshi K, Kajiyama K. Utility of lavage cytology plus targeted biopsy during cholangioscopy for the diagnosis of indeterminate biliary lesions. *Gastroenterol Hepatol Endosc* 2017; **2:** 1-4 [DOI: 10.15761/ghe.1000142]

31 **Bang JY**, Navaneethan U, Hasan M, Sutton B, Hawes R, Varadarajulu S. Optimizing Outcomes of Single-Operator Cholangioscopy-Guided Biopsies Based on a Randomized Trial. *Clin Gastroenterol Hepatol* 2020; **18**: 441-448.e1 [PMID: 31351135 DOI: 10.1016/j.cgh.2019.07.035]

32 **Fung BM**, Tabibian JH. Biliary endoscopy in the management of primary sclerosing cholangitis and its complications. *Liver Res* 2019; **3**: 106-117 [PMID: 31341699 DOI: 10.1016/j.livres.2019.03.004]

33 **Stiehl A**, Rudolph G, Klöters-Plachky P, Sauer P, Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. *J Hepatol* 2002; **36**: 151-156 [PMID: 11830325 DOI: 10.1016/s0168-8278(01)00251-3]

34 **Aabakken L**, Karlsen TH, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau JM, Färkkilä M, Fickert P, Hirschfield GM, Laghi A, Marzioni M, Fernandez M, Pereira SP, Pohl J, Poley JW, Ponsioen CY, Schramm C, Swahn F, Tringali A, Hassan C. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. *Endoscopy* 2017; **49**: 588-608 [PMID: 28420030 DOI: 10.1055/s-0043-107029]

35 **Waldthaler A**, Schramm C, Bergquist A. Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis. *Eur J Med Genet* 2021; **64**: 104231 [PMID: 33905896 DOI: 10.1016/j.ejmg.2021.104231]

36 **Njei B**, McCarty TR, Varadarajulu S, Navaneethan U. Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. *Aliment Pharmacol Ther* 2016; **44**: 1139-1151 [PMID: 27696456 DOI: 10.1111/apt.13817]

37 **Arnelo U**, von Seth E, Bergquist A. Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. *Endoscopy* 2015; **47**: 696-702 [PMID: 25826274 DOI: 10.1055/s-0034-1391845]

38 **Kaura K**, Sawas T, Bazerbachi F, Storm AC, Martin JA, Gores GJ, Abu Dayyeh BK, Topazian MD, Levy MJ, Petersen BT, Chandrasekhara V. Cholangioscopy Biopsies Improve Detection of Cholangiocarcinoma When Combined with Cytology and FISH, but Not in Patients with PSC. *Dig Dis Sci* 2020; **65**: 1471-1478 [PMID: 31571103 DOI: 10.1007/s10620-019-05866-2]

39 **Fujisawa T**, Ushio M, Takahashi S, Yamagata W, Takasaki Y, Suzuki A, Okawa Y, Ochiai K, Tomishima K, Ishii S, Saito H, Isayama H. Role of Peroral Cholangioscopy in the Diagnosis of Primary Sclerosing Cholangitis. *Diagnostics (Basel)* 2020; **10** [PMID: 32365686 DOI: 10.3390/diagnostics10050268]

40 **Sandha G**, D'Souza P, Halloran B, Montano-Loza AJ. A Cholangioscopy-Based Novel Classification System for the Phenotypic Stratification of Dominant Bile Duct Strictures in Primary Sclerosing Cholangitis-the Edmonton Classification. *J Can Assoc Gastroenterol* 2018; **1**: 174-180 [PMID: 31294358 DOI: 10.1093/jcag/gwy020]

41 **Tyberg A**, Raijman I, Siddiqui A, Arnelo U, Adler DG, Xu MM, Nassani N, Sejpal DV, Kedia P, Nah Lee Y, Gress FG, Ho S, Gaidhane M, Kahaleh M. Digital Pancreaticocholangioscopy for Mapping of Pancreaticobiliary Neoplasia: Can We Alter the Surgical Resection Margin? *J Clin Gastroenterol* 2019; **53**: 71-75 [PMID: 29517713 DOI: 10.1097/MCG.0000000000001008]

42 **De Luca L**, Repici A, Koçollari A, Auriemma F, Bianchetti M, Mangiavillano B. Pancreatoscopy: An update. *World J Gastrointest Endosc* 2019; **11**: 22-30 [PMID: 30705729 DOI: 10.4253/wjge.v11.i1.22]

43 **Bokemeyer A**, Gross D, Brückner M, Nowacki T, Bettenworth D, Schmidt H, Heinzow H, Kabar I, Ullerich H, Lenze F. Digital single-operator cholangioscopy: a useful tool for selective guidewire placements across complex biliary strictures. *Surg Endosc* 2019; **33**: 731-737 [PMID: 30006839 DOI: 10.1007/s00464-018-6334-6]

44 **Pillai S**, Zhou GX, Arnaud P, Jiang H, Butler WJ, Zhang H. Antibodies to endometrial transferrin and alpha 2-Heremans Schmidt (HS) glycoprotein in patients with endometriosis. *Am J Reprod Immunol* 1996; **35**: 483-494 [PMID: 8738720 DOI: 10.3748/wjg.v23.i22.4064]

45 **Imanishi M**, Ogura T, Kurisu Y, Onda S, Takagi W, Okuda A, Miyano A, Amano M, Nishioka N, Masuda D, Higuchi K. A feasibility study of digital single-operator cholangioscopy for diagnostic and therapeutic procedure (with videos). *Medicine (Baltimore)* 2017; **96**: e6619 [PMID: 28403110 DOI: 10.1097/MD.0000000000006619]

46 **Natov NS**, Horton LC, Hegde SR. Successful endoscopic treatment of an intraductal papillary neoplasm of the bile duct. *World J Gastrointest Endosc* 2017; **9**: 238-242 [PMID: 28572878 DOI: 10.4253/wjge.v9.i5.238]

47 **Gunasingam N**, Craig PI. Cholangioscopy-directed radiofrequency ablation of complex biliary cholangiocarcinoma. *VideoGIE* 2019; **4**: 211-213 [PMID: 31061941 DOI: 10.1016/j.vgie.2018.12.017]

48 **Livraghi T**, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. *Radiology* 2003; **226**: 441-451 [PMID: 12563138 DOI: 10.1148/radiol.2262012198]

49 **Wadsworth CA**, Westaby D, Khan SA. Endoscopic radiofrequency ablation for cholangiocarcinoma. *Curr Opin Gastroenterol* 2013; **29**: 305-311 [PMID: 23449026 DOI: 10.1097/MOG.0b013e32835faacc]

50 **Larghi A**, Rimbaș M, Tringali A, Boškoski I, Rizzatti G, Costamagna G. Endoscopic radiofrequency biliary ablation treatment: A comprehensive review. *Dig Endosc* 2019; **31**: 245-255 [PMID: 30444547 DOI: 10.1111/den.13298]

51 **Talreja JP**, DeGaetani M, Sauer BG, Kahaleh M. Photodynamic therapy for unresectable cholangiocarcinoma: contribution of single operator cholangioscopy for targeted treatment. *Photochem Photobiol Sci* 2011; **10**: 1233-1238 [PMID: 21512706 DOI: 10.1039/c0pp00259c]

52 **Chahal P**, Baron TH. Endoscopic palliation of cholangiocarcinoma. *Curr Opin Gastroenterol* 2006; **22**: 551-560 [PMID: 16891889 DOI: 10.1097/01.mog.0000239872.12081.a4]

53 **Ortner ME**, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. *Gastroenterology* 2003; **125**: 1355-1363 [PMID: 14598251 DOI: 10.1016/j.gastro.2003.07.015]

54 **Greif F**, Bronsther OL, Van Thiel DH, Casavilla A, Iwatsuki S, Tzakis A, Todo S, Fung JJ, Starzl TE. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. *Ann Surg* 1994; **219**: 40-45 [PMID: 8297175 DOI: 10.1097/00000658-199401000-00007]

55 **Boeva I**, Karagyozov PI, Tishkov I. Post-liver transplant biliary complications: Current knowledge and therapeutic advances. *World J Hepatol* 2021; **13**: 66-79 [PMID: 33584987 DOI: 10.4254/wjh.v13.i1.66]

56 **Martins FP**, Ferrari AP. Cholangioscopy-assisted guidewire placement in post-liver transplant anastomotic biliary stricture: efficient and potentially also cost-effective. *Endoscopy* 2017; **49**: E283-E284 [PMID: 28905337 DOI: 10.1055/s-0043-117940]

57 **Franzini T**, Sagae VMT, Guedes HG, Sakai P, Waisberg DR, Andraus W, D'Albuquerque LAC, Sethi A, de Moura EGH. Cholangioscopy-guided steroid injection for refractory post liver transplant anastomotic strictures: a rescue case series. *Ther Adv Gastrointest Endosc* 2019; **12**: 2631774519867786 [PMID: 31489404 DOI: 10.1177/2631774519867786]

58 **Moy BT**, Birk JW. A Review on the Management of Biliary Complications after Orthotopic Liver Transplantation. *J Clin Transl Hepatol* 2019; **7**: 61-71 [PMID: 30944822 DOI: 10.14218/JCTH.2018.00028]

59 **Wu W**, Faigel DO, Sun G, Yang Y. Non-radiation endoscopic retrograde cholangiopancreatography in the management of choledocholithiasis during pregnancy. *Dig Endosc* 2014; **26**: 691-700 [PMID: 24861135 DOI: 10.1111/den.12307]

60 **Barakat MT**, Girotra M, Choudhary A, Huang RJ, Sethi S, Banerjee S. A prospective evaluation of radiation-free direct solitary cholangioscopy for the management of choledocholithiasis. *Gastrointest Endosc* 2018; **87**: 584-589.e1 [PMID: 28797911 DOI: 10.1016/j.gie.2017.07.042]

61 **Brewer Gutierrez OI**, Godoy Brewer G, Zulli C, Tejaswi S, Pawa R, Jamidar P, Robles-Medranda C, Pawa S, Camilion JV, Oleas R, Parsa N, Runge T, Miaw D, Ichkhanian Y, Khashab MA. Multicenter experience with digital single-operator cholangioscopy in pregnant patients. *Endosc Int Open* 2021; **9**: E116-E121 [PMID: 33532547 DOI: 10.1055/a-1320-0084]

62 **Achanta CR**. Radiation-free removal of common bile duct stones in pregnancy facilitated by endoscopic ultrasound and single-operator cholangioscopy. *Endoscopy* 2021; **53**: E100-E101 [PMID: 32659801 DOI: 10.1055/a-1202-1248]

63 **Uradomo L**, Pandolfe F, Aragon G, Borum ML. SpyGlass cholangioscopy for management of choledocholithiasis during pregnancy. *Hepatobiliary Pancreat Dis Int* 2011; **10**: 107 [PMID: 21269945 DOI: 10.1016/s1499-3872(11)60017-9]

64 **Sanaka MR**, Wadhwa V, Patel M. Retrieval of proximally migrated biliary stent with direct peroral cholangioscopy with an ultraslim endoscope. *Gastrointest Endosc* 2015; **81**: 1483-1484 [PMID: 25865384 DOI: 10.1016/j.gie.2015.01.029]

65 **Ogura T**, Okuda A, Miyano A, Nishioka N, Higuchi K. Migrated endoclip removal after cholecystectomy under digital single-operator cholangioscopy guidance. *Endoscopy* 2018; **50**: E74-E75 [PMID: 29329478 DOI: 10.1055/s-0043-124758]

66 **Al Lehibi A**, Al Mtawa A, Almasoudi T, Al Ghamdi A, Al Otaibi N, Al Balkhi A. Removal of proximally migrated biliary stents by using single-operator cholangioscopy. *VideoGIE* 2020; **5**: 213-216 [PMID: 32426574 DOI: 10.1016/j.vgie.2020.01.001]

67 **Bas-Cutrina F**, Garcia-Sumalla A, Velasquez J, Consiglieri CF, Lladó L, Gornals JB. Removal of a migrated biliary stent using new digital cholangioscopy retrieval devices in a transplant patient. *Endoscopy* 2019; **51**: E323-E324 [PMID: 31163480 DOI: 10.1055/a-0916-8490]

68 **Zhang L**, Craig PI. A case of hemobilia secondary to cancer of the gallbladder confirmed by cholangioscopy and treated with a fully covered self-expanding metal stent. *VideoGIE* 2018; **3**: 381-383 [PMID: 30506001 DOI: 10.1016/j.vgie.2018.08.013]

69 **Sum Foong K**, Lee A, Kudakachira S, Ramberan H. Hemobilia from Biliary Angiodysplasia Diagnosed with Cholangioscopy. *ACG Case Rep J* 2016; **3**: e132 [PMID: 27807584 DOI: 10.14309/crj.2016.105]

70 **Kedia P**, Kuo V, Tarnasky P. Digital cholangioscopy-assisted endoscopic gallbladder drainage. *Gastrointest Endosc* 2017; **85**: 257-258 [PMID: 27449190 DOI: 10.1016/j.gie.2016.07.016]

71 **Gutkin E**, Hussain SA, Kim SH. The Successful Treatment of Chronic Cholecystitis with SpyGlass Cholangioscopy-Assisted Gallbladder Drainage and Irrigation through Self-Expandable Metal Stents. *Gut Liver* 2012; **6**: 136-138 [PMID: 22375186 DOI: 10.5009/gnl.2012.6.1.136]

72 **Tyberg A**, Zerbo S, Kahaleh M, Sharaiha RZ. Digital cholangioscopy-assisted gallbladder drainage: seeing is accessing. *Endoscopy* 2015; **47 Suppl 1 UCTN**: E417 [PMID: 26397847 DOI: 10.1055/s-0034-1392655]

73 **Shi L**, Lin S, Yao J, Li F. A novel endoscopic method for removal of giant calcified stool bezoar by cholangioscopy-guided electric hydraulic lithotripsy. *Gastrointest Endosc* 2019; **90**: 531-532 [PMID: 31077703 DOI: 10.1016/j.gie.2019.05.002]

74 **ASGE Technology Committee**, Komanduri S, Thosani N, Abu Dayyeh BK, Aslanian HR, Enestvedt BK, Manfredi M, Maple JT, Navaneethan U, Pannala R, Parsi MA, Smith ZL, Sullivan SA, Banerjee S. Cholangiopancreatoscopy. *Gastrointest Endosc* 2016; **84**: 209-221 [PMID: 27236413 DOI: 10.1016/j.gie.2016.03.013]

75 **Deprez PH**, Garces Duran R, Moreels T, Furneri G, Demma F, Verbeke L, Van der Merwe SW, Laleman W. The economic impact of using single-operator cholangioscopy for the treatment of difficult bile duct stones and diagnosis of indeterminate bile duct strictures. *Endoscopy* 2018; **50**: 109-118 [PMID: 29172216 DOI: 10.1055/s-0043-121268]

76 **Karagyozov P**, Boeva I, Tishkov I. Role of digital single-operator cholangioscopy in the diagnosis and treatment of biliary disorders. *World J Gastrointest Endosc* 2019; **11**: 31-40 [PMID: 30705730 DOI: 10.4253/wjge.v11.i1.31]

77 **Gravito-Soares M**, Almeida N. Peroral Cholangiopancreatoscopy: New Advances Bring New Concerns. *GE Port J Gastroenterol* 2018; **25**: 112-114 [PMID: 29761145 DOI: 10.1159/000486019]

78 **Lübbe J**, Arnelo U, Lundell L, Swahn F, Törnqvist B, Jonas E, Löhr JM, Enochsson L. ERCP-guided cholangioscopy using a single-use system: nationwide register-based study of its use in clinical practice. *Endoscopy* 2015; **47**: 802-807 [PMID: 25910063 DOI: 10.1055/s-0034-1391990]

79 **Turowski F**, Hügle U, Dormann A, Bechtler M, Jakobs R, Gottschalk U, Nötzel E, Hartmann D, Lorenz A, Kolligs F, Veltzke-Schlieker W, Adler A, Becker O, Wiedenmann B, Bürgel N, Tröger H, Schumann M, Daum S, Siegmund B, Bojarski C. Diagnostic and therapeutic single-operator cholangiopancreatoscopy with SpyGlassDS™: results of a multicenter retrospective cohort study. *Surg Endosc* 2018; **32**: 3981-3988 [PMID: 29532224 DOI: 10.1007/s00464-018-6141-0]

80 **Murabayashi T**, Ogawa T, Koshita S, Kanno Y, Kusunose H, Sakai T, Masu K, Yonamine K, Miyamoto K, Kozakai F, Endo K, Noda Y, Ito K. Peroral Cholangioscopy-guided Electrohydraulic Lithotripsy with a SpyGlass DS Versus a Conventional Digital Cholangioscope for Difficult Bile Duct Stones. *Intern Med* 2020; **59**: 1925-1930 [PMID: 32389946 DOI: 10.2169/internalmedicine.4463-20]

81 **Xu MM**, Kahaleh M. Recent developments in choledochoscopy: technical and clinical advances. *Clin Exp Gastroenterol* 2016; **9**: 119-124 [PMID: 27274300 DOI: 10.2147/CEG.S84020]

82 **Subhash A**, Abadir A, Iskander JM, Tabibian JH. Applications, Limitations, and Expansion of Cholangioscopy in Clinical Practice. *Gastroenterol Hepatol (N Y)* 2021; **17**: 110-120 [PMID: 34035770]

83 **Boston Scientific Corporation.** An Expanding Suite of Compatible Accessories and Applications. [cited June 23, 2021]. Available from: https://www.bostonscientific.com/en-EU/products/direct-visualization-systems/spyglass-ds-direct-visualization-system/accessories-and-applications.html

**Footnotes**

**Conflict-of-interest statement:** There are no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 30, 2021

**First decision:** July 29, 2021

**Article in press:** January 17, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Maetani I **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR


**Figure Legends**

****

**Figure 1 Common diagnostic and therapeutic applications of cholangioscopy.**



**Figure 2 SpyGlassTM DS accessories including: AutolithTM Touch biliary electrohydraulic lithotripsy probe, Lumenis SlimLineTM SIS GITM holmium laser lithotripsy probe, SpyBiteTM Max biopsy forceps, SpyGlass retrieval snare, and SpyGlass retrieval basket (left to right).** Additional accessories are expected to be developed over time[83]. Image adapted with permission from Dr. Isaac Raijman and Boston Scientific. Citation: **Boston Scientific Corporation.** An Expanding Suite of Compatible Accessories and Applications. [cited June 23, 2021]. Available from: https://www.bostonscientific.com/en-EU/products/direct-visualization-systems/spyglass-ds-direct-visualization-system/accessories-and-applications.html. Copyright© 2022. Published by SpyGlass™ DS.



**Figure 3 Example of an indeterminate biliary stricture further evaluated by cholangioscopy, initially thought to be Mirizzi syndrome secondary to chronic choledocholithiasis.** A: Magnetic resonance cholangiopancreatography (T2 HASTE, coronal projection) demonstrating cholelithiasis, choledocholithiasis, and right hepatic ductal dilation as well as possible common hepatic duct (CHD) obstruction (arrow); B: Endoscopic retrograde cholangiopancreatography (ERCP) showing 1.5 cm CHD stricture suspicious for perihilar cholangiocarcinoma (CCA); C: Frond-like growth and neovascularization suggestive of neoplasm involving the CHD, later confirmed as perihilar CCA following SpyBiteTM Max biopsy (previously with negative cytology on initial ERCP); D and E: Multiple views of the hepatic ducts that demonstrate scant reactive changes (from prior plastic biliary stent) and proximal limit of disease extension/tumor mapping; F: ERCP confirming successful deployment of plastic biliary stent across CHD stricture and subsequent decompression of right hepatic duct.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**